Showing 1 - 4 of 4 Lymphoma
A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Sharell Cornett-Risher

Phone: 713.441.3250

This is an open-label, dose-escalation/dose-expansion study of INCB057643 in subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic a ... Read more >

A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies

Status: Open Not Enrolling

Investigator: Monisha Singh

Study Coordinator: Ashley Towne

Phone: 346.238.2006

This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult patients with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The patient population durin ... Read more >

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Ashley Towne

Phone: 346.238.2006

Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations

Status: Active

Investigator: Swaminathan Iyer

Study Coordinator: Sharell Cornett-Risher

Phone: 713.441.3250

This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 monotherapy and R-907 (rituximab in combination with CUDC-907) in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Dif ... Read more >